NEW YORK — Geneoscopy said Tuesday that it has received a laboratory permit from the New York State Department of Health.
With the permit, obtained under the department's Clinical Laboratory Evaluation Program, Geneoscopy can now provide its services, including its ColoSense colorectal cancer screening test, in all 50 US states and the District of Columbia.
ColoSense is a lab test that uses RNA markers and occult hemoglobin in stool to detect colorectal cancer, advanced adenomas, and serrated precancerous lesions. It was approved by the US Food and Drug Administration in May for the screening of individuals at least 45 years old who have an average risk for developing colorectal cancer.
St. Louis-based Geneoscopy is currently involved in litigation with Exact Sciences over intellectual property related to the companies' respective colon cancer screening tests.